Search research articles
Contact Us
Filters
Showing results (81-90 of 313) with videos related to
Page
of 32
Sort By:
Gastroenterology
|
March 16, 2010
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel
Jasmine Bahrami, Bernardo Yusta, Daniel J Drucker
The Journal of Biological Chemistry
|
April 30, 2002
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase
Bernardo Yusta, Jennifer Estall, Daniel J Drucker
Nature Reviews. Drug Discovery
|
April 2, 2010
Liraglutide
Daniel J Drucker, Argyris Dritselis, Peter Kirkpatrick
JAMA
|
September 15, 2025
New Molecules and Indications for GLP-1 Medicines
Maria J Gonzalez-Rellan, Daniel J Drucker
Endocrinology
|
October 9, 2004
Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells
Grace Flock, Xiemin Cao, Daniel J Drucker
Cell Reports. Medicine
|
July 16, 2025
The expanding benefits of GLP-1 medicines
Maria J Gonzalez-Rellan, Daniel J Drucker
Cell Reports. Medicine
|
December 17, 2025
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Susanna Fang, Fiona Cui, Daniel J Drucker
Endocrinology
|
October 11, 2008
Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse
Irene Hadjiyanni, Kunmin Karen Li, Daniel J Drucker
The New England Journal of Medicine
|
January 18, 2008
Clinical decisions. Management of type 2 diabetes
Ronald B Goldberg, Rury Holman, Daniel J Drucker
Endocrinology
|
July 21, 2011
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells
Jacqueline A Koehler, Taylor Kain, Daniel J Drucker
Page
of 32
Search research articles
Search
Showing results (81-90 of 313) with videos related to
Sort By:
Page
of 32
Gastroenterology
|
March 16, 2010
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel
Jasmine Bahrami, Bernardo Yusta, Daniel J Drucker
The Journal of Biological Chemistry
|
April 30, 2002
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase
Bernardo Yusta, Jennifer Estall, Daniel J Drucker
Nature Reviews. Drug Discovery
|
April 2, 2010
Liraglutide
Daniel J Drucker, Argyris Dritselis, Peter Kirkpatrick
JAMA
|
September 15, 2025
New Molecules and Indications for GLP-1 Medicines
Maria J Gonzalez-Rellan, Daniel J Drucker
Endocrinology
|
October 9, 2004
Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells
Grace Flock, Xiemin Cao, Daniel J Drucker
Cell Reports. Medicine
|
July 16, 2025
The expanding benefits of GLP-1 medicines
Maria J Gonzalez-Rellan, Daniel J Drucker
Cell Reports. Medicine
|
December 17, 2025
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Susanna Fang, Fiona Cui, Daniel J Drucker
Endocrinology
|
October 11, 2008
Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse
Irene Hadjiyanni, Kunmin Karen Li, Daniel J Drucker
The New England Journal of Medicine
|
January 18, 2008
Clinical decisions. Management of type 2 diabetes
Ronald B Goldberg, Rury Holman, Daniel J Drucker
Endocrinology
|
July 21, 2011
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells
Jacqueline A Koehler, Taylor Kain, Daniel J Drucker
Page
of 32